Holen Sie sich die Stockscreener-App
8.855
3.66%
-0.335
Schlusskurs vom Vortag:
$9.19
Offen:
$9.14
24-Stunden-Volumen:
102.32K
Relative Volume:
0.08
Marktkapitalisierung:
$481.62M
Einnahmen:
$2.85M
Nettoeinkommen (Verlust:
$-143.44M
KGV:
-3.3249
EPS:
-2.6632
Netto-Cashflow:
$-133.44M
1W Leistung:
-3.56%
1M Leistung:
-8.73%
6M Leistung:
-61.44%
1J Leistung:
+3.18%
1-Tages-Spanne:
$8.69
$9.14
1-Wochen-Bereich:
$8.69
$9.57
52-Wochen-Spanne:
$7.25
$33.68
Upstream Bio Inc Stock (UPB) Company Profile
Firmenname
Upstream Bio Inc
Sektor
Branche
Telefon
781-208-2466
Adresse
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
8.85 | 500.12M | 2.85M | -143.44M | -133.44M | -2.6632 |
VRTX
Vertex Pharmaceuticals Inc
|
426.40 | 108.54B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
708.50 | 75.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.49 | 50.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.43 | 40.45B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.22 | 32.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-12-18 | Eingeleitet | Mizuho | Outperform |
| 2025-11-18 | Eingeleitet | Evercore ISI | Outperform |
| 2025-10-14 | Eingeleitet | Truist | Buy |
| 2024-11-05 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-05 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-05 | Eingeleitet | TD Cowen | Buy |
| 2024-11-05 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Upstream Bio Inc Aktie (UPB) Neueste Nachrichten
Jennison Associates LLC Makes New Investment in Upstream Bio, Inc. $UPB - MarketBeat
UPB Stock Price, Quote & Chart | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
Upstream Bio down despite mid-stage trial win for asthma drug - MSN
Upstream Bio (UPB) price target decreased by 10.31% to 44.37 - MSN
Upstream Bio lead drug pivotal trial plan follows strong phase 2 data - MSN
UPB Forecast, Price Target & Analyst Ratings | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
Segment Overview and Major Growth Areas in the Upstream Bioprocessing Market - openPR.com
Chronic Obstructive Pulmonary Disease Clinical Trial Landscape Expands: Over 65 Companies Advancing Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Upstream Bio, Inc. (NASDAQ:UPB) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Upstream Bio (UPB) Stock Bonus Issue (Bearish Sentiment) 2026-04-20Bullish Pattern - Newser
Upstream Bio (UPB) Stock Ask Wall (Trend Weakens) 2026-04-18Upside Potential - Cổng thông tin điện tử tỉnh Lào Cai
Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference - Sahm
Upstream Bio to present verekitug data at medical conference By Investing.com - Investing.com Australia
Upstream Bio to present verekitug data at medical conference - Investing.com
Can Upstream Bio (UPB) Stock Beat Estimates | Price at $10.24, Down 2.38%AI Stock Signals - Newser
Bull Bear: Is Upstream Bio Inc a cyclical or defensive stock2026 Intraday Action & Low Drawdown Trading Strategies - baoquankhu1.vn
UPB Options Volatility — NASDAQ:UPB - TradingView — Track All Markets
UPB Options Chain — NASDAQ:UPB - TradingView
Validating the IL-13/TSLP Axis: Upstream Bio’s Verekitug Positioned for Differentiated Asthma Efficacy and Favorable Risk–Reward - TipRanks
Earnings Update: Is Upstream Bio Inc still a buy after recent gains2026 Rallies & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB) and Pfizer (PFE) - The Globe and Mail
Truist cuts Upstream Bio stock price target on trial timeline By Investing.com - Investing.com Canada
Market Recap: Is Upstream Bio Inc forming a bullish divergence2026 Volume & Daily Chart Pattern Signals - baoquankhu1.vn
Piper Sandler Maintains UpStream Bio(UPB.US) With Buy Rating, Maintains Target Price $75 - Moomoo
Upstream Bio, Inc. (UPB) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Retail Surge: Does Upstream Bio Inc have a sustainable dividendTrade Signal Summary & Verified Trade Idea Suggestions - baoquankhu1.vn
UpStream Bio | 10-K: FY2025 Annual Report - Moomoo
Upstream Bio, Inc. (NASDAQ:UPB) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Upstream Bio (NASDAQ:UPB) Rating Lowered to Sell at Wall Street Zen - MarketBeat
VALIANT Asthma Trial Update: What Upstream Bio’s Phase 2 Milestone Means for Investors - TipRanks
Upstream Bio (NASDAQ:UPB) Downgraded by Evercore to In-Line - MarketBeat
A Quick Look at Today's Ratings for UpStream Bio(UPB.US), With a Forecast Between $15 to $42 - moomoo.com
Finanzdaten der Upstream Bio Inc-Aktie (UPB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Upstream Bio Inc-Aktie (UPB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Deykin Aaron | Chief Medical Officer |
Mar 16 '26 |
Sale |
9.29 |
894 |
8,305 |
32,687 |
| Sutherland Everett Rand | Chief Executive Officer |
Mar 16 '26 |
Sale |
9.29 |
2,093 |
19,444 |
72,907 |
| Ambrose Allison | General Counsel |
Mar 16 '26 |
Sale |
9.29 |
475 |
4,413 |
16,525 |
| Houghton Adam | Chief Business Officer |
Mar 16 '26 |
Sale |
9.29 |
699 |
6,494 |
24,301 |
5.78%
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):